CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by StockNews.com

CytomX Therapeutics (NASDAQ:CTMX) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Tuesday.

Separately, JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a research report on Monday.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX traded up $0.01 during mid-day trading on Tuesday, reaching $1.68. 290,171 shares of the company traded hands, compared to its average volume of 840,418. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $2.86. The firm has a market cap of $113.79 million, a PE ratio of -83.96 and a beta of 1.01. The stock has a fifty day simple moving average of $2.05 and a 200-day simple moving average of $1.64.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The company had revenue of $26.61 million for the quarter, compared to analyst estimates of $23.36 million. As a group, analysts predict that CytomX Therapeutics will post -0.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total value of $42,266.07. Following the transaction, the chief executive officer now owns 524,481 shares in the company, valued at $1,096,165.29. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 35,024 shares of company stock worth $73,200. 7.00% of the stock is owned by insiders.

Institutional Trading of CytomX Therapeutics

Several large investors have recently added to or reduced their stakes in CTMX. AlphaMark Advisors LLC raised its stake in CytomX Therapeutics by 119.8% during the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 12,635 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of CytomX Therapeutics by 737.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 234,970 shares in the last quarter. Finally, Congress Park Capital LLC grew its holdings in shares of CytomX Therapeutics by 112.8% during the 4th quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 126,850 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.